Tag Archives: 510(k)

FDA’s Last Guidances for 2012

FDA closed out 2012 by releasing several new guidance documents, including: FDA Oversight of PET Drug Products — Questions and Answers Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs Specifications for Preparing and Submitting Summary Level Clinical Site … Continue reading

Posted in Clinical Trials, eCTD, FDA, Regulatory Strategy | Tagged , , , , , , , , , , , | Comments Off on FDA’s Last Guidances for 2012

New Guidances from FDA for October 2012

FDA released four notable new guidances in October 2012, with a focus on guidances related to medical devices: Guidance: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs — Questions and Answers (R1) Guidance: FDA and … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , | Comments Off on New Guidances from FDA for October 2012

De novo device reclassification: What have you done for me lately?

The recently passed FDA Safety and Innovation Act makes major changes to the de novo reclassification process for medical devices.  Namely, the new law mandates that a manufacturer can simply submit a request to the FDA for de novo classification … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , | Comments Off on De novo device reclassification: What have you done for me lately?

FDASIA, Part 2: Pediatric Drugs and Devices and Medical Device Regulatory Improvements

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part weekly series, we are covering the major changes in FDASIA as follows: Part 1: … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , | 3 Comments

FDASIA, Part 1: The “UFAs”

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part series, we will cover the major changes in FDASIA as follows: Part 1: The … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , , | 4 Comments